V-5 Immunitor: Interim Phase IIb data

Interim data from 34 patients at a second clinical site in the ongoing, double-blind, Ukrainian Phase IIb Study imm01 trial showed that once-daily oral V5 plus standard

Read the full 278 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE